The Lancet Oncology
Access articles from The Lancet Oncology, covering topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology
Related Articles
Best of 2024: Top Features From Cancer Therapy Advisor
This page includes links to Cancer Therapy Advisor’s top feature articles published in 2024.
Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients
Genetic markers for venetoclax could help personalize treatment and improve outcomes
Registration
Registration details for AACR IO: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy
Navigating the Blood Cancer Journey: What Everyone Should Know
Victor Gonzalez of The Lymphoma Research Foundation talks hope, mindfulness, identity, and treatment.
AACR Distinguished Lectureship recipient offers insight into invasive lobular carcinoma research – SABCS Meeting News
Steffi Oesterreich, PhD, on Thursday shared highlights from her seminal fundamental and translational research on invasive lobular carcinoma.
How the 2024 elections can impact cancer policy – The Cancer Letter
As we come within a stone’s throw of Nov. 5, we can’t help but wonder if and how the election outcome will impact health care…
AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients
Discover emerging themes and early-stage clinical oncology pipelines at the second AACR Oncology Industry Partnership event.
January 2025 – OCE ENGAGE – Project Community
Click to share this newsletter with your friends! Welcome to the January 2025 edition of the FDA Oncology Center of Excellence (OCE) quarterly newsletter from…
SSO President Update: ACT 2025 with Dr. Senthil
Watch this latest SSO President Update featuring Maheswari Senthil, MD, discussing details of the upcoming Advanced Cancer Therapies meeting taking place in …
Bortezomib combined with ibrutinib/rituximab in the first-line treatment of WM
Christian Buske, MD, University Hospital Ulm, Ulm, Germany, discusses findings from the ECWM-2 trial (NCT03620903), which evaluated the combination of ibrutinib, rituximab, and bortezomib for…
